Please use this identifier to cite or link to this item:
Title: Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'
Authors: Saad, E. D.
BUYSE, Marc 
Issue Date: 2016
Source: ANNALS OF ONCOLOGY, 27(8), p. 1653-1653
Notes: [Saad, E. D.; Buyse, M.] Int Drug Dev Inst, Louvain La Neuve, Belgium. [Saad, E. D.] Dendrix Res, Sao Paulo, Brazil. [Buyse, M.] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Diepenbeek, Belgium.
Document URI:
ISSN: 0923-7534
e-ISSN: 1569-8041
DOI: 10.1093/annonc/mdw196
ISI #: 000383182800046
Rights: © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email:
Category: A1
Type: Journal Contribution
Validations: ecoom 2017
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
  Restricted Access
Version in press36.7 kBAdobe PDFView/Open    Request a copy
Show full item record

Page view(s)

checked on May 19, 2022


checked on May 19, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.